reference/26349185

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26349185

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article
endingPage	2432
issn	1078-0432 1557-3265
issueIdentifier	10
pageRange	2423-2432
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	2423
bibliographicCitation	Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM. Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 May 15;23(10):2423–32. doi: 10.1158/1078-0432.ccr-16-1782. PMID: 27815358.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e5dea2ba66665739e31fbd1e072cabf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8c53be08b1ff005487ee17d0098511a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a58754ef19e32fac655b2101a3cd6781 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00359f4dea2659383ce72344ae64ce6d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4497d696cefb472975989638e8f7b424 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ea804eeb8196941dfcf38c03581be19 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_045075f74ef1fe8260c641f8266d517c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4831c9b9ed96210404e04cee87dacd39 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4079c16509ca2f1446ecd611ccb09197 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf57e591f97f82e9c18f17addb09168a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ba2eaf58e03af2d34cf7d88fd96eb533 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b650d007b9c62ae26d9c57776bc30b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d390243b8ac07ed93ee3a867e26e19a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7d119764b5c585e7010ca5855a39f6b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c04411973257c04af5ffd3c265c3ab4c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d6f51cb2f0ec983119a108ca80dbc84 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa77f7f6a7f7e1691f0cf819a0c55457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60a9bf8b53af0d6a1ff756dda20a1037
date	2017-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/27815358 https://doi.org/10.1158/1078-0432.ccr-16-1782
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
discusses	http://id.nlm.nih.gov/mesh/M0217020 http://id.nlm.nih.gov/mesh/M0010294 http://id.nlm.nih.gov/mesh/M0217014 http://id.nlm.nih.gov/mesh/M0016885 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M000626311
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006575Q000008 http://id.nlm.nih.gov/mesh/D010880Q000008 http://id.nlm.nih.gov/mesh/D008545Q000188 http://id.nlm.nih.gov/mesh/D064726Q000188 http://id.nlm.nih.gov/mesh/D000071877Q000037
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006575Q000009 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D064726Q000235 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D000071877Q000235 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D010880Q000009 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008545Q000235 http://id.nlm.nih.gov/mesh/D064726Q000473 http://id.nlm.nih.gov/mesh/D064420Q000473 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008545Q000473 http://id.nlm.nih.gov/mesh/D018572
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9350 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1ab93dab864d412d37c9dcb9c25f8a38 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8620 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58266779 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_848ea8bb1121ee393ad72ae0d412d8d2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c343e6a7c6ed1f53a79a52a5af338d66 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aeebd1980c6662678028fc899ba441eb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1111

Total number of triples: 94.